President-elect Donald Trump’s appointment of a slate of new antitrust regulators is predicted to herald a more favourable climate for healthcare mergers and acquisitions. That, at least, is the expectation, as well as hope, of lawyers who have worked on healthcare deals that have become ensnared in litigation and regulatory challenges under the outgoing administration. During the presidency of Joe Biden, the healthcare industry has been one of the main targets for regulators. Their actions have ranged from attempting to tackle private equity “roll-up” schemes accused of creating monopoly pricing power for hospital and clinic networks, to scrutinising the influence of pharmacy intermediaries in drug pricing investigations.
Read the full article: US Healthcare Deal Advisers Seek Lighter Supervision //
Source: https://www.ft.com/content/0b057bc2-a719-4446-8141-794c357b1ff6